Sanofi
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Vir Biotechnology Enhances Portfolio with Sanofi Deal and Executive Appointments
Vir Biotechnology finalized a global licensing deal with Sanofi for three clinical-stage T-cell engagers and a protease-cleavable masking platform, paying $100 million initially and potentially over $1.8 billion, plus royalties. The deal also transfers key Sanofi employees to Vir. Vir appointed Jason O’Byrne as CFO and Brent Sabatini as principal accounting officer.
Media Update: ERS: Dupixent data reinforce clinically meaningful benefit from pooled ...
Dupixent showed a 31% reduction in COPD exacerbations and improved lung function in a pooled analysis of BOREAS and NOTUS phase 3 studies, reinforcing its clinical benefit for uncontrolled COPD patients with type 2 inflammation.
Vir Biotechnology closes Sanofi licence deal for T-cell engagers
Vir Biotechnology has finalized an exclusive worldwide license agreement with Sanofi, gaining access to clinical-stage T-cell engagers (TCEs) and the PRO-XTEN masking platform for oncology and infectious disease. The deal includes three TCEs targeting distinct cancer markers and leverages the PRO-XTEN technology to enhance therapeutic index by selectively activating within the tumor microenvironment.
Transgene Appoints Two Seasoned Leaders in Oncology to Drive its Next Phase of Innovation
Transgene appoints Dr. Emmanuelle Dochy as CMO and Dr. Maurizio Ceppi as CSO to advance cancer immunotherapies and precision medicine.
Vir Biotechnology secures Sanofi cancer drug licenses
Vir Biotechnology finalized a licensing deal with Sanofi, gaining exclusive rights to three cancer therapies using Sanofi's PRO-XTENTM platform. The deal includes SAR446309, SAR446329, and SAR446368, targeting HER2+ tumors, metastatic castration-resistant prostate cancer, and EGFR-expressing tumors, respectively. Vir's CEO, Marianne De Backer, is optimistic about these therapies' potential. Financial terms were undisclosed, but the acquisition is pivotal for Vir's oncology and infectious disease portfolio expansion.
Vir Biotechnology Announces Closing of Exclusive Worldwide License Agreement With ...
Vir Biotechnology secures exclusive worldwide license for three clinical-stage masked T-cell engagers (TCEs) and the PRO-XTEN masking platform from Sanofi, enhancing its oncology and infectious disease capabilities. The agreement includes SAR446309 (HER2-targeted TCE), SAR446329 (PSMA-targeted TCE), and SAR446368 (EGFR-targeted TCE), with clinical studies underway or planned. The PRO-XTEN platform aims to improve therapeutic index by selectively activating drug candidates in tumor tissues.
Vir Biotechnology Announces Closing of Exclusive Worldwide License Agreement With Sanofi
Vir Biotechnology closed an exclusive worldwide license agreement with Sanofi, gaining three clinical-stage masked T-cell engagers (TCEs) for cancer treatment and the PRO-XTEN masking platform for oncology and infectious disease. The agreement includes SAR446309 for HER2+ tumors, SAR446329 for prostate cancer, and SAR446368 for EGFR-expressing tumors, with clinical studies to commence. Key Sanofi employees with TCE expertise will join Vir, enhancing its drug discovery capabilities.
The Highly Anticipated FDA Approvals of Galderma's Nemolizumab and Eli Lilly's
Despite declining use of Sanofi/Regeneron’s Dupixent due to competition from LEO’s Adbry, Pfizer’s Cibinqo, and AbbVie’s Rinvoq, the overall population receiving advanced treatments for atopic dermatitis is rising, according to Spherix Global Insights. Dermatologists estimate that two-fifths of adult atopic dermatitis patients now receive advanced systemic treatments, highlighting the demand for effective AD treatments. The potential approvals of Galderma’s nemolizumab and Eli Lilly’s lebrikizumab could further shift physician preferences, with nemolizumab expected to gain more adoption than lebrikizumab.
mRNA Vaccine Market Size to Achieve USD 9.6 Billion Revenue
The global mRNA vaccine market is projected to decline at a CAGR of -4.3% from 2024 to 2034, reaching US$ 9.6 billion by 2034. Factors driving market growth include streamlined approval processes, innovations in logistics, increasing public trust, and ongoing research into long-term efficacy. Key players include Pfizer-BioNTech, Moderna, and Novartis, with North America leading in market share.
© Copyright 2025. All Rights Reserved by MedPath